Interview: KoBioLabs Pioneering The Microbiome Landscape In Korea

Industry interest in the development of microbiome modulators is noticeably increasing worldwide. In South Korea, KoBioLabs is leading the charge to microbiome drug development, helped by a sizable database and biobank. Its founder and CEO GwangPyo Ko talked to Scrip about its core technology, pipeline progress, and general strategy.

GwangPyo Ko, founder and CEO of KoBioLabs Inc. — GwangPyo Ko, Founder and CEO of KoBioLabs • Source: KoBioLabs Inc.

Amid a global boom in microbiome drug development in recent years, industry interest, R&D, and investment in this promising new therapeutic sector is also rising in South Korea.

KoBioLabs Inc., founded by the country's most renowned microbiome scientist GwangPyo Ko, is pioneering local efforts using differentiated platform technologies...